RegRapPod: InConversation

FAMHP: The role of the Belgian Agency in advancing public health

33 min · 18 jun 2025
aflevering FAMHP: The role of the Belgian Agency in advancing public health artwork

Beschrijving

In this episode of RegRapPod – InConversation, host Claire McDermott and members of TOPRA’s Benelux Steering Group talk with Hugues Malonne, Chief Executive Officer of Belgium’s Federal Agency for Medicines and Health Products (FAMHP) about the Agency’s strategic priorities, its role in shaping and facilitating European legislation and how it collaborates with other regulators, both within and outside the EU.

Reacties

0

Wees de eerste die een reactie plaatst

Meld je nu aan en word lid van de RegRapPod: InConversation community!

Probeer gratis

Probeer 14 dagen gratis

€ 9,99 / maand na proefperiode. · Elk moment opzegbaar.

  • Podcasts die je alleen op Podimo hoort
  • 20 uur luisterboeken / maand
  • Gratis podcasts

Alle afleveringen

9 afleveringen

aflevering Joint Clinical Assessment: How to align your regulatory and access strategies artwork

Joint Clinical Assessment: How to align your regulatory and access strategies

In this episode of RegRapPod – InConversation, host Claire McDermott talks with Sangeeta Budhia, Senior Vice President and Global Head of Pricing, Market Access and Evidence Evaluation, and Sinan Sarac, Senior Vice President and Head of Oncology Europe, Regulatory Consulting, both at Parexel, about Joint Clinical Assessment (JCA) implementation in Europe. Established under Regulation EU 2021/2282, with the aim of providing a standardised process for evaluating clinical evidence of health technologies, the JCA process is mandatory. It was implemented in January 2025 for oncology drugs and cell and gene therapies and extends to orphan drugs in 2028 and all products in 2030. This podcast walks listeners through not only the basics of JCA, but also the key challenges in preparing submissions, how to navigate them, how to integrate your evidence generation strategy and how JCA will influence regulatory strategy and clinical development planning for future products.

28 jan 202633 min